Anemia is common in patients with chronic kidney disease and is associated with a high
burden of morbidity and adverse clinical outcomes. In 2012, Kidney Disease: Improving …

Chronic kidney disease (CKD) affects approximately 10% of the worldwide population;
anaemia is a frequent complication. Inadequate erythropoietin production and absolute or …

Renal anemia in chronic kidney disease (CKD) is associated with poor outcomes. Hypoxia-
inducible factor (HIF) stabilizer, which induces endogenous erythropoietin synthesis and …

The production of erythropoietin (EPO), the main regulator of erythroid differentiation, is
regulated by hypoxia-inducible factor (HIF). HIF2α seems to be the principal regulator of …

Background Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) are new
therapeutic agents for anaemia in chronic kidney disease (CKD). We evaluated by meta …

Background: Anemia is a common complication of chronic kidney disease. The hypoxia-
inducible factor prolyl hydroxylase inhibitor (HIF-PHI) is a new class of oral drugs for the …

Aim: We performed a systematic review and network meta-analysis evaluating the safety
and efficacy of hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) among …

Daprodustat, one of several oral hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-
PHIs) that have undergone clinical trials for the treatment of anemia in people with CKD on …

Anemia is one of the most common chronic kidney disease (CKD) complications. It
negatively affects patients' quality of life and clinical outcomes. The pathophysiology of …

Hypoxia-inducible factor-prolyl hydroxylase domain inhibitors (HIF-PHIs) are a novel group
of drugs used to treat renal anemia, but their benefits vary among different trials. Our meta …